Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common supplement curb stroke damage?

NCT ID NCT07749287

Disease control Sponsor: Helwan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This phase 3 trial investigates whether N-acetyl cysteine (NAC), an antioxidant supplement, can improve recovery in people hospitalized with an acute ischemic stroke. Participants receive either NAC or a placebo (saline) shortly after admission, and researchers track their neurological function and markers of inflammation. The goal is to see if NAC can reduce stroke-related disability and dampen the body's harmful inflammatory response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
N-acetyl cysteine (NAC) given as a 600 mg oral solution every 8 hours for 3 days after hospital admission
What this could lead to
If NAC proves effective, it could offer a simple, widely available treatment to improve recovery and reduce disability after an acute ischemic stroke.
What could go wrong
This is a single-center trial with a modest number of participants, and results may not generalize. NAC's benefits beyond standard care remain uncertain, and it is not a replacement for clot-busting drugs when those are appropriate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

121 people

The number who actually took part.

Started

Jun 2021

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age above 18 years * AIS patients admitted into stroke unit * Onset within 48 hours * Glasgow coma scale (GCS) ≥ 8 * Out of window or contraindicated for thrombolytics * Not arrested before Exclusion Criteria: * Age below 18 years * Cerebral haemorrhage * Dural sinus thrombosis * Glasgow coma scale (GCS) \< 8 * Patients received thrombolytic * Post arrest

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebral infarction ischemic stroke myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic cerebral infarction

Contacts and locations

Locations

  • Stroke Unit, Neurology Department, Kasr Al Ainy, Cairo University Hospital

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.